Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Samstein, RM; Krishna, C; Ma, XX; Pei, X; Lee, KW; Makarov, V; Kuo, FS; Chung, J; Srivastava, RM; Purohit, TA; Hoen, DR; Mandal, R; Setton, J; Wu, W; Shah, R; Qeriqi, B; Chang, Q; Kendall, S; Braunstein, L; Weigelt, B; Albornoz, PBC; Morris, LGT; Mandelker, DL; Reis, JS; de Stanchina, E; Powell, SN; Chan, TA; Riaz, N

Chan, TA; Riaz, N (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA.; Chan, TA; Riaz, N (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.; Chan, TA; Riaz, N (corresponding author), Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, 1275 York Ave, New York, NY 10021 USA.; Chan, TA (corresponding author), Cleveland Clin, Dept Radiat Oncol, Ctr Immunotherapy & Precis Immunooncol, Cleveland, OH 44106 USA.

NATURE CANCER, 2020; 1 (12): 1188

Abstract

Immune checkpoint blockade (ICB) has improved outcomes for patients with advanced cancer, but the determinants of response remain poorly understood. H......

Full Text Link